Pulmonary hypertension: animal modeling and molecular mechanism

doi:10.3877/cma.j.issn.1674-0785.2019.02.012

Abstract

Abstract:

Pulmonary arterial hypertension (PAH) is a fatal disease that is characterized by hypertrophic pulmonary vascular remodeling of distal arterioles to increase pulmonary artery pressure and pulmonary vascular resistance. The pathological mechanism of PAH is very complicated and many pathogenic factors are involved in this process. This review will focus on the roles of ion homeostasis, bone morphogenetic proteins, vasoactive substances, and other cell signal factors in PAH, with an aim to provide new therapeutic targets for molecular intervention for PAH and early clinical rehabilitation intervention. For this purpose, we provide an overview of the development of several animal models of PAH and discusses several key signaling factors contributing to the vascular remodeling process.

Key words: Pulmonary arterial hypertension, Animal model, Molecular mechanism

Hui Shen, Zhengang Zhang, Kaizheng Gong. Pulmonary hypertension: animal modeling and molecular mechanism[J]. Chinese Journal of Clinicians(Electronic Edition), 2019, 13(02): 141-146.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2019.02.012

https://zhlcyszz.cma-cmc.com.cn/EN/Y2019/V13/I02/141

References 46

1	Vaillancourt M, Ruffenach G, Meloche J, et al. Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension [J]. Can J Cardiol, 2015, 31(4): 407-415.
2	Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease [J]. Annu Rev Physiol, 2012, 74: 13-40.
3	Xu D, Li Y, Zhang B, et al. Resveratrol alleviate hypoxic pulmonary hypertension via anti-inflammation and anti-oxidant pathways in rats [J]. Int J Med Sci, 2016, 13(12): 942-954.
4	Naeije R, Dedobbeleer C. Pulmonary hypertension and the right ventricle in hypoxia [J]. Exp Physiol, 2013, 98(8): 1247-1256.
5	Nogueira-Ferreira R, Vitorino R, Ferreira R, et al. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach [J]. Pulm Pharmacol Ther, 2015, 35: 8-16.
6	Gomez-Arroyo J, Saleem SJ, Mizuno S, et al. A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects [J]. Am J Physiol Lung Cell Mol Physiol, 2012, 302(10): L977-L991.
7	Strobl M, Schreiber C, Panzenböck A, et al. Exhaled nitric oxide measurement to monitor pulmonary hypertension in a pneumonectomy-monocrotaline rat model [J]. Am J Physiol Lung Cell Mol Physiol, 2013, 305(7): 485-490.
8	Soon E, Crosby A, Southwood M, et al. Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension [J]. Am J Respir Crit Care Med, 2015, 192(7): 859-872.
9	Davies RJ, Holmes AM, Deighton J, et al. BMP type II receptor deficiency confers resistance to growth inhibition by TGF-beta in pulmonary artery smooth muscle cells: role of proinflammatory cytokines [J]. Am J Physiol Lung Cell Mol Physiol, 2012, 302(6): L604-L615.
10	Calvier L, Chouvarine P, Legchenko E, et al. PPARγ links BMP2 and TGFβ1 pathways in vascular smooth muscle cells, regulating cell proliferation and glucose metabolism [J]. Cell Metab, 2017, 25(5): 1118-1134.
11	Shimoda LA, Polak J. Hypoxia. 4. Hypoxia and ion channel function [J]. Am J Physiol Cell Physiol, 2011, 300(5): C951-C967.
12	Song S, Yamamura A, Yamamura H, et al. Flow shear stress enhances intracellular Ca^2＋ signaling in pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension [J]. Am J Physiol Cell Physiol, 2014, 307(4): C373-C383.
13	王益波, 马改改, 陈安, 等. 特发性肺动脉高压发病机制的新进展 [J]. 中国循环杂志, 2015, 30(6): 605-607.
14	Bonnet S, Rochefort G, Sutendra G, et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted [J]. Proc Natl Acad Sci USA, 2007, 104(27): 11418-11423.
15	Hayabuchi Y. The action of smooth muscle cell potassium channels in the pathology of pulmonary arterial hypertension [J]. Pediatr Cardiol, 2017, 38(1): 1-14.
16	Huetsch JC, Jiang H, Larrain C, et al. The Na^＋/H^＋ exchanger contributes to increased smooth muscle proliferation and migration in a rat model of pulmonary arterial hypertension [J]. Physiol Rep, 2016, 4(5). pii: e12729.
17	Huetsch J, Shimoda LA. Na(^＋)/H(^＋) exchange and hypoxic pulmonary hypertension [J]. Pulm Circ, 2015, 5(2): 228-243.
18	Yu L, Hales CA. Silencing of sodium-hydrogen exchanger 1 attenuates the proliferation, hypertrophy, and migration of pulmonary artery smooth muscle cells via E2F1 [J]. Am J Respir Cell Mol Biol, 2011, 45(5): 923-930.
19	王瑾, 向莉莉, 李晓晖. 骨形成蛋白Ⅱ型受体信号通路与肺动脉高压:新进展与希望 [J]. 中国药理学与毒理学杂志, 2017, 31(2): 119-130.
20	Cai J, Pardali E, Sanchez-Duffhues G, et al. BMP signaling in vascular diseases [J]. FEBS letters, 2012, 586(14): 1993-2002.
21	Lowery JW, de Caestecker MP. BMP signaling in vascular development and disease [J]. Cytokine Growth Factor Rev, 2010, 21(4): 287-298.
22	Yang J, Li X, Al-Lamki RS, et al. Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension [J]. Arterioscler Thromb Vasc Biol, 2013, 33(1): 34-42.
23	Broege A, Pham L, Jensen ED, et al. Bone morphogenetic proteins signal via SMAD and mitogen-activated protein (MAP) kinase pathways at distinct times during osteoclastogenesis [J]. J Biol Chem, 2013, 288(52): 37230-37240.
24	Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension [J]. Turk Kardiyol Dern Ars, 2014, 42 Suppl 1: 17-28.
25	Diebold I, Hennigs J, Miyagawa K, et al. BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension [J]. Cell Metab, 2015, 21(4): 596-608.
26	Hopper RK, Moonen JA, Diebold I, et al. In pulmonary arterial hypertension, reduced BMPR2 promotes endothelial-to-mesenchymal transition via HMGA1 and its target Slug [J]. Circulation, 2016, 133(18): 1783-1794.
27	Orriols M, Gomez-Puerto MC, Ten Dijke P. BMP type Ⅱ receptor as a therapeutic target in pulmonary arterial hypertension [J]. Cell Mol Life Sci, 2017, 74(16): 2979-2995.
28	Meloche J, Pflieger A, Vaillancourt M, et al. Role for DNA damage signaling in pulmonary arterial hypertension [J]. Circulation, 2014, 129(7): 786-797.
29	Li M, Vattulainen S, Aho J, et al. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension [J]. Am J Respir Cell Mol Biol, 2014, 50(6): 1118-1128.
30	Khadka A, Singh Brashier DB, Tejus A, et al. Macitentan: An important addition to the treatment of pulmonary arterial hypertension [J]. J Pharmacol Pharmacother, 2015, 6(1): 53-57.
31	Yu J, Taylor L, Wilson J, et al. Altered expression and signal transduction of endothelin-1 receptors in heritable and idiopathic pulmonary arterial hypertension [J]. J Cell Physiol, 2013, 228(2): 322-329.
32	Kij A, Mateuszuk L, Sitek B, et al. Simultaneous quantification of PGI2 and TXA2 metabolites in plasma and urine in NO-deficient mice by a novel UHPLC/MS/MS method [J]. J Pharm Biomed Anal, 2016, 129: 148-154.
33	Falcetti E, Hall SM, Phillips PG, et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension [J]. Am J Respir Crit Care Med, 2010, 182(9): 1161-1170.
34	Chu LY, Liou JY, Wu KK. Prostacyclin protects vascular integrity via PPAR/14-3-3 pathway [J]. Prostaglandins Other Lipid Media, 2015, 118-119: 19-27.
35	Chen YC, Chu LY, Yang SF, et al. Prostacyclin and PPARalpha agonists control vascular smooth muscle cell apoptosis and phenotypic switch through distinct 14-3-3 isoforms [J]. PloS one, 2013, 8(7): e69702.
36	Romero M, Toral M, Robles-Vera I, et al. Activation of peroxisome proliferator activator receptor β/δ improves endothelial dysfunction and protects kidney in murine lupus [J]. Hypertension, 2017, 69(4): 641-650.
37	Ahmadian M, Suh JM, Hah N, et al. PPARgamma signaling and metabolism: the good, the bad and the future [J]. Nat Med, 2013, 19(5): 557-566.
38	Liu Y, Tian XY, Mao G, et al. Peroxisome proliferator-activated receptor-gamma ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor [J]. Hypertension, 2012, 60(6): 1471-1478.
39	Bertero T, Cottrill K, Krauszman A, et al. The microRNA-130/301 family controls vasoconstriction in pulmonary hypertension [J]. J Biol Chem, 2015, 290(4): 2069-2085.
40	Bertero T, Yu L, Annis S, et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension [J]. J Clin Invest, 2014, 124(8): 3514-3528.
41	Hansmann G, de Jesus Perez VA, Alastalo TP, et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension [J]. J Clin Invest, 2008, 118(5): 1846-1857.
42	Chen YF, Feng JA, Li P, et al. Dominant negative mutation of the TGF-beta receptor blocks hypoxia-induced pulmonary vascular remodeling [J]. J Appl Physiol, 2006, 100(2): 564-571.
43	Gong K, Xing D, Li P, et al. Hypoxia induces downregulation of PPAR-gamma in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor-beta signaling [J]. Am J Physiol Lung Cell Mol Physiol, 2011, 301(6): L899-L907.
44	刘洪涛, 曾艳, 苟德明. 缺氧诱导因子1调控缺氧性肺动脉高压的研究进展 [J]. 中华高血压杂志, 2014, 22(7): 629-634.
45	Li Y, Shi B, Huang L, et al. Suppression of the expression of hypoxia-inducible factor-1alpha by RNA interference alleviates hypoxia-induced pulmonary hypertension in adult rats [J]. Int J Mol Med, 2016, 38(6): 1786-1794.
46	Abud EM, Maylor J, Undem C, et al. Digoxin inhibits development of hypoxic pulmonary hypertension in mice [J]. Proc Natl Acad Sci U S A, 2012, 109(4): 1239-1244.

[1]	Yuqing Huang, Dudu Wu, Fei Pan, Junkang Wang, Zhaoming Zhong, Tanshi Li, Faqin Lyu. Application of handheld ultrasound in establishment of a swine model of iliac artery hemorrhage from gunshot wound [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2022, 19(10): 1112-1117.
[2]	Hongxin Shi, Zhifang Tang, Minzheng Guo, Luqiao Pu, Baochuang Qi, Junxiao Ren, Chuan Li. Exploration of methodology and role of sodium iodoacetate in modeling of rat osteoarthritis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(04): 534-539.
[3]	Chuanju Li, Linyue Liu, Mei Wang, Xin Li, Xianghui Han, Haiyong Jia. Progress on models of hepatitis B virus infection [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2022, 16(06): 361-365.
[4]	Lina Wu, Lin Wei, Zhigui Zeng, Liang Zhang, Enhui He, Yule Tan, Zhijun Zhu, Liying Sun. Pulmonary arterial hypertension targeted drugs combined with liver transplantation for severe portalpulmonary hypertension: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(06): 376-378.
[5]	Shifeng Shao, Zhengbin Wu, Chaoxia Duan, Liangchao Zhang, Yaoli Wang, Qi Li, Jianmin Wang. Establishment of a model of severe primary lung blast injury in goats at high altitude [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(05): 637-642.
[6]	Xiaomei Liu, Lu Zhang, Xu Liu, Die Liang. Effects of miR-127-3p targeting macrophage migration inhibitory factor on the biological behavior of human renal cancer cells [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(02): 76-83.
[7]	Zhuolin Li, Ruxue Jia, Yating Wu, Shenghang Zhang, Shuiliang Wang. Advances in molecular mechanisms underlying tumor metastasis and its targeted intervention [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2022, 12(01): 51-58.
[8]	Xi Jin, Kang Sun, Jian Guo, Mei Kong. Research progress in the mechanism of colorectal cancer liver metastases [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(02): 163-166.
[9]	Qinglin Li, Renjie Song, Feihu Zhou. Establishment and exploration of a mouse model of severe exertional heat stroke-related acute kidney injury [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(05): 265-270.
[10]	Jinyu Jiang, Donglei Zhang, Wei He. Advances in the application of blue light induced-oxidative damage models in the study of ophthalmic diseases [J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(03): 168-172.
[11]	Jian Li, Yong Tao, Shuyi Li, Xiaohua Zhang, Yongping Hu. Research progress of cytokines and ophthalmic diseases [J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(02): 115-119.
[12]	Ming Lu, Bo Yang, Yang Liu, Hui Wang, Wen Hong, Kelin Huang, Qing Liu. Establishment of a large animal model of anal incontinence [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(04): 356-361.
[13]	Qiaoli Guo, Hui Hu. Application of patient-derived xenograft model in study of triple-negative breast cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(10): 790-793.
[14]	Shikai Li, Jia Liang, Yanyan He, Yi Yu, Tianxiao Li, Jinlong Chang, Yingkun He. Research progress of carotid atherosclerotic stenosis rabbit model for interventional therapy [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(04): 357-362.
[15]	Fei Gao, Huikai Li, Xiuxue Feng, Chen Du, Ke Han, Ningli Chai, Enqiang Linghu. Cystic tumor ablation with 3% lauromacrogol solution in an animal model [J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2023, 10(01): 31-36.

Please choose a citation manager

Content to export